Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...

Find out all you need to know about bispecific antibodies, including how they work and what the current clinical landscape ...

According to Biospace.com "The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, exhibiting a growth ...

The European Society for Medical Oncology’s annual meeting this week featured the hottest emergent areas of cancer ...

a bispecific monoclonal antibody that binds to vascular endothelial growth factor A and programmed cell death protein 1 (PD-1), head-to-head with Merck's Keytruda, a PD-1 binding checkpoint ...

Keytruda is an antibody that binds to programmed death receptors (PD-1) on the surface of immune cells. This checkpoint is supposed to keep those cells from destroying healthy tissue, but tumor ...